Bonamichi-Santos Rafael, Castells Mariana
Division of Rheumatology, Immunology and Allergy; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Curr Pharm Des. 2016;22(45):6870-6880. doi: 10.2174/1381612822666161025154506.
Chemotherapies drugs and monoclonal antibodies are key components of the treatment of cancer patients and patients with chronic inflammatory conditions to provide increase in life expectancy and quality of life. Their increased use has lead to an increase in drugs hypersensitivity reactions (DHR) worldwide. DHR to those agents prevented their use and promoted the use of second line therapies to protect patients' hypersensitive reactions and anaphylaxis. Second line medications may not fully address the patients' medical condition and it is desirable to keep patients on first line therapy. Drug hypersensitivity symptoms can range from mild cutaneous reactions to life-threatening anaphylaxis. Rapid drug desensitization (RDD) is a novel approach to the management of drug hypersensitivity reactions which are IgE and non-IgE mediated. Through the diferent desensitization protocols patients can receive the full dose of the medications that they have presented a hypersensitive reaction and been protected against anaphylaxis. This review looks at the current literature on hypersensitivity reactions (HSR) to chemotherapy drugs and monoclonal antibodies and the potential use of RDD for their management.
化疗药物和单克隆抗体是治疗癌症患者和慢性炎症患者的关键组成部分，有助于延长预期寿命和提高生活质量。它们使用的增加导致全球药物超敏反应（DHR）增多。对这些药物的超敏反应阻碍了其使用，并促使使用二线疗法来预防患者的超敏反应和过敏反应。二线药物可能无法完全解决患者的病情，因此让患者继续使用一线疗法是可取的。药物超敏症状范围从轻度皮肤反应到危及生命的过敏反应。快速药物脱敏（RDD）是一种治疗IgE和非IgE介导的药物超敏反应的新方法。通过不同的脱敏方案，患者可以接受曾使其出现超敏反应的药物的全剂量，并预防过敏反应。本综述探讨了目前关于化疗药物和单克隆抗体超敏反应（HSR）的文献，以及RDD在其管理中的潜在应用。
